{
    "nctId": "NCT00671918",
    "briefTitle": "Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma",
    "officialTitle": "A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek\u00ae and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Melanoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 186,
    "primaryOutcomeMeasure": "Concordance of Blue Dye and Lymphoseek",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The patient has provided written informed consent with HIPAA authorization before participating in the study, as has his/her responsible caregiver, if applicable.\n* The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan.\n* The patient is at least 18 years of age at the time of consent.\n* The patient has an ECOG performance status of Grade 0 - 2 \\[8\\].\n* The patient has a clinical negative node status at the time of study entry.\n* If of child bearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.\n* The patient is currently not participating in another investigational drug study.\n\nMelanoma Patients\n\n* The patient has a diagnosis of primary melanoma.\n\nBreast Cancer Patients\n\n* The patient has a diagnosis of primary breast cancer.\n* Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan.\n\nExclusion Criteria:\n\n* The patient is pregnant or lactating;\n* The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T,N0,M0);\n* The patient has a known hypersensitivity to Lymphazurin or Patent Bleu V.\n\nMelanoma Patients\n\n* The patient has a tumor with a Breslow depth less than 0.75mm.;\n* Patients that have had preoperative chemotherapy, immunotherapy or radiation therapy;\n* Patients diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin;\n* Patients who have undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma;\n* Patients who have undergone a wide excision for their primary melanoma (\\>1 cm in dimension) or complex reconstruction (rotation, free flap or skin graft of any type).\n\nBreast Cancer Patients\n\n* The patient has bilateral primary breast cancers or multiple tumors within their breast;\n* Patients that have had prior surgical procedures such as breast implants, reduction mammoplasty or axillary surgery;\n* Patients scheduled for bilateral mastectomy for any reason;\n* Patients that have had preoperative radiation therapy to the affected breast or axilla",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}